By Andrés Cárdenas-O'Farrill, Cuban economist, associate researcher, Academic-Industry Research Network (theAIRnet)
Pharma 3.0 is gradually becoming the new paradigm in the healthcare industry among scholars, industry experts, and practitioners. This new approach is said to be the result of significant healthcare reforms in key pharmaceutical markets in the wake of the many challenges faced by the industry (e.g., low R&D productivity, tighter capital environments). But what’s peculiar is that this new trend, or at least a significant part of it, might find a distinguishable, if somewhat neglected, forerunner in the Cuban biotech industry. That may sound far-fetched at first, but let’s take a closer look to see if there are some plausible explanations.